search
Back to results

Preoperative Ketamine and Perioperative Depression

Primary Purpose

Depressive Disorder

Status
Withdrawn
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Ketamine Group
Midazolam injection
Sponsored by
Northwestern University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depressive Disorder

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patients age ≥ 65 years
  • Planned lumbar surgery for degenerative disc disease or spinal stenosis involving 2 or more levels
  • A life history of MDD (DSM-5 criteria) and a MADRS score ≥20
  • Mini-Mental State Examination (MMSE) score ≥ 15
  • MMSE is between15-26
  • Ability to understand English.

Exclusion Criteria:

  • MMSE < 15
  • History of psychosis
  • Poorly controlled hypertension
  • Current opioid use before surgery
  • Pre-existing aneurysmal vascular disorders
  • Cocaine or other illicit drug use.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Ketamine Group

    MIdazolam Group

    Arm Description

    Ketamine 0.5 mg/kg over 40 min via intravenous catheter.

    Midazolam 0.045 mg/kg administered via intravenous catheter.

    Outcomes

    Primary Outcome Measures

    Change in depressive symptoms in the perioperative period.
    Ketamine administration changes depressive symptoms perioperatively. Measured using Depression will be measured with the Montgomery-Asberg Depression Scale (MADRS) scale. Scale ranges from 0 no depresson- 60 severe depression.

    Secondary Outcome Measures

    Change in depressive symptoms 1 day after surgery
    Change in depressive symptoms using MADRS questionnaire measured with the Montgomery-Asberg Depression Scale scale. Scale ranges from 0 no depresson- 60 severe depression.
    Safety analsysis of administration of a sub-anesthetic dose of ketamine: CADSS
    To assess for the safety of administration of a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) given 1 to 3 days before surgery in the preoperative clinic (as an outpatient) by assessment of dysphoric symptoms or other complications including the need for hospitalization. The Clinician-Administered Dissociative States Scale CADSS is a 27 question survey ,19 which are completed by the subject on a scale of 0 -4 likert scale for a possible score 0- good 76 poor and 9 questions completed by the assessor (scored yes or no).

    Full Information

    First Posted
    January 3, 2020
    Last Updated
    February 2, 2023
    Sponsor
    Northwestern University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04220125
    Brief Title
    Preoperative Ketamine and Perioperative Depression
    Official Title
    Preoperative Ketamine as a Strategy to Decrease Perioperative Depression During the Perioperative Period: a Randomized Active Controlled Pilot Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2023
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    No enrollment
    Study Start Date
    September 1, 2022 (Actual)
    Primary Completion Date
    February 2, 2023 (Actual)
    Study Completion Date
    February 2, 2023 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Northwestern University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Depressive symptoms, in patients with a life history of major depressive disorder (MDD), are very common in the general population, and are especially so in elderly adults undergoing surgery.Symptoms of depression at the time of surgery is associated with risk for postoperative complications.Attenuating depressive symptoms in patients undergoing surgery is thus a plausible but not adequately tested strategy for improving patient postoperative outcomes. Conventional treatment of depression takes weeks and, therefore, is not always a realistic option, particularly when surgery is urgent. Importantly, there are currently no guidelines for diagnosing and managing MDD in surgical patients. Given its association with complications including perioperative cognitive disorders such as delirium, and over longer periods of time with dementing disorders, the feasibility and efficacy of quick-acting treatments for depressive symptoms in surgical patients are direly needed. This need is particularly acute given the rising number of elderly patients undergoing surgery who are prone to depression and surgical complications. Aim 1: To assess the feasibility of enrolling patients in a clinical trial where a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) or midazolam (0.045 mg/kg) is given 1 to 3 days before surgery in the preoperative clinic as a strategy to improve depressive symptoms during the perioperative period. Aim 2: To obtain estimates of the variability in improvements of depressive symptoms (increase from baseline in MADRS score ≥ 2)1 day after surgery for patients given a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) 1 to 3 days before surgery compared with midazolam 0.045 mg/kg. Aim 3: To assess for the safety and tolerability of administration of a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) given 1 to 3 days before surgery in the preoperative clinic (as an outpatient) by assessment of dysphoric symptoms or other complications including the need for hospitalization. Hypothesis: Aim 1: Hypothesis: Patients with preoperative depressive symptoms can be identified before surgery and successfully enrolled in a clinical trial comparing a sub-anesthetic dose of ketamine versus midazolam for improving perioperative depressive symptoms. Aim 2: Hypothesis: Compared with midazolam, a sub-anesthetic dose of ketamine given preoperatively leads to an improvement in MADRS score ≥ 2 on day 1 after surgery. Aim 3: Hypothesis: Compared with midazolam, a sub-anesthetic dose of ketamine is not associated with dysphoria or other complications.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Depressive Disorder

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare Provider
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Ketamine Group
    Arm Type
    Experimental
    Arm Description
    Ketamine 0.5 mg/kg over 40 min via intravenous catheter.
    Arm Title
    MIdazolam Group
    Arm Type
    Active Comparator
    Arm Description
    Midazolam 0.045 mg/kg administered via intravenous catheter.
    Intervention Type
    Drug
    Intervention Name(s)
    Ketamine Group
    Other Intervention Name(s)
    Ketamine
    Intervention Description
    Ketamine intravenous administration 0.5 mg/kg over 40 minutes.
    Intervention Type
    Drug
    Intervention Name(s)
    Midazolam injection
    Other Intervention Name(s)
    Midazolam
    Intervention Description
    Midazolam intravenous administration 0.045 mg/kg IV over 40 minutes.
    Primary Outcome Measure Information:
    Title
    Change in depressive symptoms in the perioperative period.
    Description
    Ketamine administration changes depressive symptoms perioperatively. Measured using Depression will be measured with the Montgomery-Asberg Depression Scale (MADRS) scale. Scale ranges from 0 no depresson- 60 severe depression.
    Time Frame
    3 Days before surgery to 30 days after the surgical procedure
    Secondary Outcome Measure Information:
    Title
    Change in depressive symptoms 1 day after surgery
    Description
    Change in depressive symptoms using MADRS questionnaire measured with the Montgomery-Asberg Depression Scale scale. Scale ranges from 0 no depresson- 60 severe depression.
    Time Frame
    24 hours after surgical procedure
    Title
    Safety analsysis of administration of a sub-anesthetic dose of ketamine: CADSS
    Description
    To assess for the safety of administration of a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) given 1 to 3 days before surgery in the preoperative clinic (as an outpatient) by assessment of dysphoric symptoms or other complications including the need for hospitalization. The Clinician-Administered Dissociative States Scale CADSS is a 27 question survey ,19 which are completed by the subject on a scale of 0 -4 likert scale for a possible score 0- good 76 poor and 9 questions completed by the assessor (scored yes or no).
    Time Frame
    65 minutes after study drug has been infused.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female patients age ≥ 65 years Planned lumbar surgery for degenerative disc disease or spinal stenosis involving 2 or more levels A life history of MDD (DSM-5 criteria) and a MADRS score ≥20 Mini-Mental State Examination (MMSE) score ≥ 15 MMSE is between15-26 Ability to understand English. Exclusion Criteria: MMSE < 15 History of psychosis Poorly controlled hypertension Pre-existing aneurysmal vascular disorders Cocaine or other illicit drug use.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Charles Hogue, MD
    Organizational Affiliation
    Northwestern University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Preoperative Ketamine and Perioperative Depression

    We'll reach out to this number within 24 hrs